Crestor 10 mg
Pro Research Analysisby 
Searched over 200M research papers
Crestor 10 mg: Efficacy, Safety, and Impact on Lipid Profile
Introduction to Rosuvastatin (Crestor)
Rosuvastatin, marketed under the trade name Crestor, is a statin medication primarily used to treat primary hypercholesterolemia and combined dyslipidemia when dietary changes alone are insufficient. It has been shown to have a significant impact on lipid profiles, making it a valuable option for patients at risk of cardiovascular diseases1 2.
Efficacy of Crestor 10 mg in Lipid Management
Reduction in LDL and Total Cholesterol
Clinical trials have demonstrated that rosuvastatin at a dosage of 10 mg is highly effective in reducing low-density lipoprotein (LDL) cholesterol and total cholesterol levels. When compared to other statins on a milligram basis, rosuvastatin provides a greater reduction in these cholesterol levels1 2. This makes it a potent option for achieving target LDL cholesterol levels in patients at risk of cardiovascular events.
Increase in HDL Cholesterol
In addition to lowering LDL cholesterol, rosuvastatin also significantly increases high-density lipoprotein (HDL) cholesterol levels. This dual action on both lowering harmful cholesterol and increasing beneficial cholesterol enhances its overall efficacy in managing dyslipidemia1 2.
Impact on Triglycerides
Rosuvastatin has been shown to decrease triglyceride levels similarly to other statins, contributing to its comprehensive lipid-modifying effects1 2.
Safety Profile of Crestor 10 mg
Comparable Safety to Other Statins
The safety profile of rosuvastatin is comparable to that of other commercially available statins. It is generally well-tolerated, with a similar incidence of adverse effects1 2. This makes it a reliable choice for long-term management of cholesterol levels.
Blood Sugar and Glucose Metabolism
A study investigating the influence of rosuvastatin on blood sugar levels in patients with coronary heart disease and hyperlipidemia found that while there was a slight increase in fasting blood glucose (FBG) and HbA1c levels in patients taking higher doses (20 mg), these changes were not statistically significant. This suggests that rosuvastatin has a good safety profile concerning glucose metabolism, even in patients at high risk of cardiovascular events3.
Dosage Considerations
Standard and Increased Dosages
The standard dosage of rosuvastatin is 10 mg daily, which is effective for most patients. However, for those with severe familial hypercholesterolemia or those who do not achieve target LDL levels with the 10 mg dose, the dosage can be increased to 20 mg or even up to 40 mg daily1 2. This flexibility allows for tailored treatment plans based on individual patient needs.
Conclusion
Rosuvastatin (Crestor) at a dosage of 10 mg is a highly effective and safe option for managing primary hypercholesterolemia and combined dyslipidemia. It significantly reduces LDL and total cholesterol levels, increases HDL cholesterol, and decreases triglycerides, with a safety profile comparable to other statins. For patients requiring more aggressive lipid management, higher dosages can be considered, maintaining good safety concerning glucose metabolism.
Sources and full results
Most relevant research papers on this topic
[Drug of the month. Rosuvastatin (Crestor)].
Rosuvastatin (Crestor) effectively reduces total and LDL cholesterol levels and increases HDL cholesterol, with a similar decrease in triglyceride levels, compared to other statins.
Le medicament du mois. Rosuvastatine (Crestor).
Rosuvastatin (Crestor) is a new statin that effectively reduces cholesterol levels and increases HDL cholesterol, with a similar decrease in triglyceride levels, compared to other statins.
Influence of Rosuvastatin on the Blood Sugar of Patients with Coronary Heart Disease Combined Hyperlipidemia
Rosuvastatin effectively reduces blood lipids and improves glucose metabolism in patients with coronary heart disease combined hyperlipidemia, with a recommended dose of 20 mg per day for high-risk patients.
Non-RCTBioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
The fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi and coadministered Lozap® AM and Crestor® are bioequivalent in terms of pharmacokinetic parameters of losartan, amlodipine, and rosuvastat
News in Brief
The new high-performance statin Crestor is more effective than older statins at lowering cholesterol, improving cardiovascular disease management in the UK.
Rosuvastatin
Rosuvastatin effectively and rapidly improves lipid profiles in patients with a broad spectrum of dyslipidemias, with higher effectiveness in those with hypercholesterolemia.
Highly CitedIs pharmaceutical detailing informative? Evidence from contraindicated drug prescriptions
Pharmaceutical detailing significantly reduces physicians' likelihood of prescribing Crestor to contraindicated patients, potentially impacting prescribing patterns.
Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study
Rosuvastatin effectively reduces LDL-C levels more effectively than pravastatin and simvastatin, with both doses meeting NCEP ATP II and EAS targets.
RCT
Large Human TrialHighly CitedSafety and efficacy of rosuvastatin
Rosuvastatin is a highly efficacious statin with a comparable safety profile to other marketed statins, and has a well-tolerated renal safety profile.
Literature Review
Rigorous Journal